Veterinary Medicines

Vanguard CPV-Lepto suspension injectable pour chiens

Authorised
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated
  • Canine parvovirus, strain NL-35-D, Live
Download as PDF

Product identification

Medicine name:
Vanguard CPV-Lepto suspension injectable pour chiens
Vanguard CPV-Lepto Injektionssuspension
Active substance:
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated
  • Canine parvovirus, strain NL-35-D, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
    40.00
    Hamster protective Dose 80 % (Ph. Eur. Monograph)
    /
    1.00
    Dose
  • Leptospira interrogans, serogroup Canicola, serovar Canicola, strain C51, Inactivated
    40.00
    Hamster protective Dose 80 % (Ph. Eur. Monograph)
    /
    1.00
    Dose
  • Canine parvovirus, strain NL-35-D, Live
    10000000.00
    cell culture infective dose 50
    /
    1.00
    Dose
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AL04
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Luxembourg
Package description:
  • Vanguard CPV-Lepto 1 dose Vial Suspension for injection
  • Vanguard CPV-Lepto 10 1 dose Vial Suspension for injection
  • Vanguard CPV-Lepto 100 1 dose Vial Suspension for injection
  • Vanguard CPV-Lepto 25 1 dose Vial Suspension for injection

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Zoetis Belgium
Marketing authorisation date:
Manufacturing sites for batch release:
  • Zoetis Belgium
Responsible authority:
  • Ministere De La Sante Division De La Pharmacie Et Des Medicaments
Authorisation number:
  • V 087/93/11/0350
Date of authorisation status change:

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
French (PDF)
Published on: 16/01/2024
Download
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."